Skip to main content

Advertisement

Log in

Autoimmune hepatitis

Evolving concepts and treatment strategies

  • Review Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Czaja AJ: Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4:1–12, 1984

    PubMed  Google Scholar 

  2. Bearn AG, Kunkel HG, Slater RJ: The problem of chronic liver disease in young women. Am J Med 21:3–15, 1956

    PubMed  Google Scholar 

  3. Mackay JR, Taft LI, Cowling DC: Lupoid hepatitis. Lancet 2:1323–1326, 1956

    Google Scholar 

  4. Czaja AJ: Current problems in the diagnosis and management of chronic active hepatitis. Mayo Clin Proc 56:311–323, 1981

    PubMed  Google Scholar 

  5. Czaja AJ: Autoimmune chronic active hepatitis—a specific entity? The negative argument. J Gastroenterol Hepatol 5:343–351, 1990

    PubMed  Google Scholar 

  6. Magrin S, Craxi A, Fiorentino G, Fabiano C, Provenzano G, Pinzello GB, Palazzo U, Almasio P, Pagliaro L: Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol 13:56–60, 1991

    PubMed  Google Scholar 

  7. Magrin S, Craxi A, Fabiano C, Fiorentino G, Almasio P, Palazzo U, Pinzello G, Provenzano G, Pagliaro L, Choo Q-L, Kuo G, Polito A, Han J, Houghton M: Hepatitis C virus replication in “autoimmune” chronic hepatitis. J Hepatol 13:364–367, 1991

    PubMed  Google Scholar 

  8. Johnson PJ, McFarlane IC, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, Czaja AJ, Desmet V, Edleston ALWF, Gerber MA, Hoofnagle JH, Kakumu S, MacSween RNM, Maddrey WC, Manns MP, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Portmann BC, Reed WD, Schalm SW, Scheuer PJ, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M: Meeting Report. International Autoimmune Hepatitis Group. Hepatology 18:998–1005, 1993

    PubMed  Google Scholar 

  9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513–1520, 1994

    PubMed  Google Scholar 

  10. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15:572–577, 1992

    PubMed  Google Scholar 

  11. Czaja AJ, Carpenter HA: Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105:1824–1832, 1993

    PubMed  Google Scholar 

  12. Maddrey WC: Subdivisions of idiopathic autoimmune chronic active hepatitis. Hepatology 7:1372–1375, 1987

    PubMed  Google Scholar 

  13. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA: The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104:1755–1761, 1993

    PubMed  Google Scholar 

  14. Czaja AJ: Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med 119:510–517, 1993

    PubMed  Google Scholar 

  15. Czaja AJ: Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 23:547–566, 1994

    PubMed  Google Scholar 

  16. Ben-Ari Z, Dhillon AP, Sherlock S: Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis. Hepatology 18:10–15, 1993

    PubMed  Google Scholar 

  17. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, Palmer JM, Heathcote EJ: Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 35:260–265, 1994

    PubMed  Google Scholar 

  18. Taylor SL, Dean PJ, Riely CA: Primary autoimmune cholangitis: an alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Clin Pathol 18:91–99, 1994

    Google Scholar 

  19. Lidman K, Biberfield G, Fagraeus A, Norberg R, Tortensson R, Utter G, Carlsson L, Luca J, Lindberg U: Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 24:266–272, 1976

    PubMed  Google Scholar 

  20. Toh B-H: Smooth muscle autoantibody and autoantigens. Clin Exp Immunol 38:621–628, 1979

    PubMed  Google Scholar 

  21. Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy V-G, Grippon P, Opolon P, Bernuau J, Benhamou J-P, Alagille D: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of “autoimmune” hepatitis. Hepatology 7:1333–1339, 1987

    PubMed  Google Scholar 

  22. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF: Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713–717, 1983

    PubMed  Google Scholar 

  23. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA: Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 18:342–352, 1993

    PubMed  Google Scholar 

  24. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18:816–822, 1993

    PubMed  Google Scholar 

  25. Perdigoto R, Carpenter HA, Czaja AJ: Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 14:325–331, 1992

    PubMed  Google Scholar 

  26. Davis GL, Czaja AJ, Ludwig J: Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 87:1222–1227, 1984

    PubMed  Google Scholar 

  27. Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF: Prognostic and therapeutic implications of extreme aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc 57:303–309, 1982

    PubMed  Google Scholar 

  28. Crapper RM, Bhathal PS, Mackay IR, Frazer IH: “Acute” autoimmune hepatitis. Digestion 34:216–225, 1986

    PubMed  Google Scholar 

  29. Amontree JS, Stuart TD, Bredfeldt JE: Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 11:303–307, 1989

    PubMed  Google Scholar 

  30. Czaja AJ, Rakela J, Ludwig J: Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95:448–453, 1988

    PubMed  Google Scholar 

  31. Nikias GA, Batts KP, Czaja AJ: The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 21:866–871, 1994

    PubMed  Google Scholar 

  32. Czaja AJ, Manns MP, Homburger HA: Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290–1295, 1992

    PubMed  Google Scholar 

  33. Manns MP, Griffin KJ, Sullivan KF, Johnson EF: LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88:1370–1378, 1991

    PubMed  Google Scholar 

  34. Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, Zauli D, Bianchi FB: Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 335:258–259, 1990

    PubMed  Google Scholar 

  35. Esteban JI, Esteban R, Viladomiu L, Lopez-Talavera JC, Gonzalez A, Hernandez JM, Roget M, Vargas V, Guardia J, Houghton M, Choo Q-L, Kuo G: Hepatitis C virus antibodies among risk groups in Spain. Lancet 2:294–297, 1989

    PubMed  Google Scholar 

  36. Todros L, Touscoz G, D'Urso N, Durazzo M, Albano E, Poli G, Baldi M, Rizzetto M: Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 13:128–131, 1991

    PubMed  Google Scholar 

  37. Garson JA, Lenzi M, Ring C, Cassani F, Ballardini G, Briggs M, Tedder RS, Bianchi FB: Hepatitis C viraemia in adults with type 2 autoimmune hepatitis. J Med Virol 34:223–226, 1991

    PubMed  Google Scholar 

  38. Michel G, Ritter A, Gerken G, Meyer zum Buschenfelde K-H, Decker R, Manns MP: Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 339:267–269, 1992

    PubMed  Google Scholar 

  39. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y, Valla D, Borotto E, Yamamoto A-M, Huraux J-M, Opolon P, Homberg J-C: Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 16:630–636, 1992

    PubMed  Google Scholar 

  40. Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP: Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 106:1603–1610, 1994

    PubMed  Google Scholar 

  41. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde K-H: Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1:292–294, 1987

    PubMed  Google Scholar 

  42. Wachter B, Kyriatsoulis A, Lohse AW, Gerken G, Meyer zum Buschenfelde K-H, Manns M: Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies. J Hepatol 11:232–239, 1990

    PubMed  Google Scholar 

  43. Czaja AJ, Carpenter HA, Manns MP: Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 105:1522–1528, 1993

    PubMed  Google Scholar 

  44. Stechemesser E, Klein R, Berg PA: Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 18:1–9, 1993

    PubMed  Google Scholar 

  45. Czaja AJ, Hay JE, Rakela J: Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 65:23–30, 1990

    PubMed  Google Scholar 

  46. Greeve M, Ferrell L, Kim M, Combs C, Roberts J, Ascher N, Wright TL: Cirrhosis of undefined pathogenesis: Absence of evidence for unknown viruses or autoimmune processes. Hepatology 17:593–598, 1993

    PubMed  Google Scholar 

  47. McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R: Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result? Lancet 335:754–757, 1990

    PubMed  Google Scholar 

  48. Nishiguchi S, Kuroki T, Ueda T, Fukuda K, Takeda T, Nakajima S, Shiomi S, Kobayashi K, Otani S, Hayashi N, Shikata T: Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis. Ann Intern Med 116:21–25, 1992

    PubMed  Google Scholar 

  49. Czaja AJ, Taswell HF, Rakela J, Rabe D: Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. Gastroenterology 102:1675–1679, 1992

    PubMed  Google Scholar 

  50. Sanchez-Tapias JM, Barrera JM, Costa J, Ercilla MG, Pares A, Comalrrena L, Soley F, Bruix J, Calvet X, Gil MP, Mas A, Bruguera M, Castillo R, Rodes J: Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 112:921–924, 1990

    PubMed  Google Scholar 

  51. Cassani F, Muratori L, Manotti P, Lenzi M, Fusconi M, Ballardini G, Selleri L, Volta U, Zauli D, Miniero R, Bianchi FB: Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: A reappraisal at the light of hepatitis C virus infection. Gut 33:1260–1263, 1992

    PubMed  Google Scholar 

  52. Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L: Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci (in press)

  53. Ma Y, Peakman M, Lenzi M, Thomas MG, Farzaneh F, Ballardini G, Casani F, Mieli-Vergani G, Bianchi FB, Vergani D: Case against subclassification of type II autoimmune chronic active hepatitis. Lancet 341:60, 1993

    Google Scholar 

  54. Vergani D, Mieli-Vergani G: Type II autoimmune hepatitis. What is the role of the hepatitis C virus? Gastroenterology 104:1870–1873, 1993 (editorial)

    PubMed  Google Scholar 

  55. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F: Characterization of the anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 104:1762–1767, 1993

    PubMed  Google Scholar 

  56. Nakatsuji Y, Matsumoto A, Tanaka E, Ogata H, Kiyosawa K: Detection of chronic hepatitis C virus infection by four diagnostic systems: First-generation and second-generation enzyme-linked immunosorbent assay, second-generation recombinant immunoblot assay and nested polymerase chain reaction analysis. Hepatology 16:300–305, 1992

    PubMed  Google Scholar 

  57. Schvarcz R, Von Sydow M, Weiland O: Autoimmune chronic active hepatitis: Changing reactivity for antibodies to hepatitis C virus after immunosuppressive treatment. Scand J Gastroenterol 25:1175–1180, 1990

    PubMed  Google Scholar 

  58. Vento S, DiPerri G, Garofano T, Cosco L, Concia E, Ferraro T, Bassetti D: Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 2:926, 1989

    PubMed  Google Scholar 

  59. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J-P: Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 116:51–53, 1992

    PubMed  Google Scholar 

  60. Shindo M, DiBisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102:1406–1408, 1992

    PubMed  Google Scholar 

  61. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Pagliaro L: Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid therapy. Hepatology 19:273–279, 1994

    PubMed  Google Scholar 

  62. Pagliaro L, Craxi A, Cammaa C, Tine F, DiMarco V, LoIacono O, Almasio P: Interferon-alfa for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 19:820–828, 1994

    PubMed  Google Scholar 

  63. Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, Gallo V, Petrino R, De Micheli AG, Solinas A, Deplano A, Tocco A, Cossu PA, Pintus C, Verme G, Rizzetto M: Antibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 11:339–343, 1990

    PubMed  Google Scholar 

  64. Tran A, Quaranta J-F, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul J-L, Hebuterne X, Rampal P: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18:253–257, 1993

    PubMed  Google Scholar 

  65. Burman P, Totterman TH, Oberg K, Karlsson FA: Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63:1086–1090, 1986

    PubMed  Google Scholar 

  66. Mayet W-J, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer zum Buschenfelde KH: Treatment of chronic type B hepatitis with recombinant alpha interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10:24–28, 1989

    PubMed  Google Scholar 

  67. Fattovich G, Betterle C, Brollo L, Giustina G, Realdi G, Alberti A, Ruol A: Autoantibodies during alfa-interferon therapy for chronic hepatitis B. J Med Virol 34:132–135, 1991

    PubMed  Google Scholar 

  68. Wee A, Ludwig J: Pericholangitis in chronic ulcerative colitis: Primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 102:581–587, 1985

    PubMed  Google Scholar 

  69. Ludwig J, Wiesner RH, La Russo NF: Idiopathic adulthood ductopenia. J Hepatol 7:193–199, 1988

    PubMed  Google Scholar 

  70. Czaja AJ, Nishioka M, Morshed SA, Hachiya T: Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107:200–207, 1994

    PubMed  Google Scholar 

  71. Tan EM, Chan EKL, Sullivan KF, Rubin RL: Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 47:121–141, 1988

    PubMed  Google Scholar 

  72. Tan EM: Antinuclear antibodies: Diagnostic markers and clues to the basis of systemic autoimmunity. Pediatr Infect Dis 7:S3-S9, 1988

    Google Scholar 

  73. Tan EM: Antinuclear antibodies. Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44:93–151, 1989

    PubMed  Google Scholar 

  74. Mackay IR: Immunological aspects of chronic active hepatitis. Hepatology 3:724–728, 1983

    PubMed  Google Scholar 

  75. Kenny RP, Czaja AJ, Ludwig J, Dickson ER: Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 31:705–711, 1986

    PubMed  Google Scholar 

  76. Zurgil N, Konikoff F, Bakimer R, Slor H, Shoenfeld Y: Detection of antimitochondrial antibodies: Characterization by enzyme immunoassay and immunoblotting. Autoimmunity 4:289–297, 1989

    PubMed  Google Scholar 

  77. Mutimer DJ, Fussey SPM, Yeaman SJ, Kelly PJ, James OFW, Bassendine MF: Frequency of IgG and IgM autoantibodies to the four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 10:403–407, 1989

    PubMed  Google Scholar 

  78. Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA, Dickson ER, Krawitt E, Coppel R, Gershwin ME: M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena? Hepatology 16:1128–1136, 1992

    PubMed  Google Scholar 

  79. Manns MP: Cytoplasmic autoantigens in autoimmune hepatitis: Molecular analysis and clinical relevance. Semin Liver Dis 11:205–214, 1991

    PubMed  Google Scholar 

  80. Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Buschenfelde K-H, Meyer UA, Eichelbaum M: Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodiesin vitro but notin vivo. Hepatology 12:127–132, 1990

    PubMed  Google Scholar 

  81. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg J-C: Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8:1662–1666, 1988

    PubMed  Google Scholar 

  82. Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S, Homberg JC: Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 16:892–898, 1992

    PubMed  Google Scholar 

  83. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschefelde K-H: Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 11:606–612, 1990

    PubMed  Google Scholar 

  84. McFarlane BM, Sipos J, Gove CD, McFarlane IG, Williams R: Antibodies against the hepatic asialoglycoprotein receptor perfusedin situ perentially attach to periportal liver cells in the rat. Hepatology 11:408–415, 1990

    PubMed  Google Scholar 

  85. Poralla T, Treichel U, Lohr H, Fleischer B: The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 11:215–222, 1991

    PubMed  Google Scholar 

  86. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Buschenfelde K-H, Poralla T: Autoantibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 19:55–63, 1993

    PubMed  Google Scholar 

  87. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R: Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 2:954–956, 1984

    PubMed  Google Scholar 

  88. Warny M, Brenard R, Cornu C, Tomasi J-P, Geubel A-P: Anti-neutrophil antibodies in chronic hepatitis and the effect of a-interferon therapy. J Hepatol 17:294–300, 1993

    PubMed  Google Scholar 

  89. Hardarson S, LaBrecque DR, Mitros FA, Neil GA, Goeken JA: Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. Am J Clin Pathol 99:277–281, 1993

    PubMed  Google Scholar 

  90. Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CGM: Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 17:411–417, 1993

    PubMed  Google Scholar 

  91. Targan S, Landers C, Vidrich A, Czaja A: High level perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) are present in almost all autoimmune hepatitis (AIH) type 1 patients. Gastroenterology 106:A997, 1994 (abstract)

    Google Scholar 

  92. Hagen EC, Ballieux BEPB, van Es LA, Daha MR, van der Woude FJ: Antineutrophil cytoplasmic autoantibodies: A review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood 81:1996–2002, 1993

    PubMed  Google Scholar 

  93. Saxon A, Shanahan F, Landers C, Ganz T, Targan S: A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 86:202–210, 1990

    PubMed  Google Scholar 

  94. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shananhan F: Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 100:1590–1596, 1991

    PubMed  Google Scholar 

  95. Cambridge G, Rampton DS, Stevens TRJ, McCarthy DA, Kamm M, Leaker B: Anti-neutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 33:668–674, 1992

    PubMed  Google Scholar 

  96. Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Shanahan F: Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 100:1385–1391, 1991

    PubMed  Google Scholar 

  97. Halbwachs-Mecarelli L, Nusbaum P, Noel LH, Reumaux D, Erlinger S, Grunfeld JP, Lesavre P: Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 90:79–84, 1992

    PubMed  Google Scholar 

  98. Lo SK, Chapman RWG, Cheeseman P, Charlton CPJ, Walker-Smith JA, Mieli-Vergani G, Fleming KA: Antineutrophil antibody: A test for autoimmune primary sclerosing cholangitis in childhood? Gut 34:199–202, 1993

    PubMed  Google Scholar 

  99. Loeper J, Descatoire V, Maurice M, Beaune P, Belghiti J, Houssin D, Ballet F, Feldmann G, Guengerich FP, Pessayre D: Cytochromes P-450 in human hepatocyte plasma membrane: Recognition by several autoantibodies. Gastroenterology 104:203–216, 1993

    PubMed  Google Scholar 

  100. Czaja AJ: Chronic graft-versus-host disease and primary biliary cirrhosis: Sorting the puzzle pieces. Lab Invest 70:589–592, 1994 (editorial)

    PubMed  Google Scholar 

  101. Williams RM, Martin S, Falchuk KR, Trey C, Dubey DP, Cannady WG, Fitzpatrick D, Noreen H, Dupont B, Yunis EJ: Increased frequency of HLA-DRW4 in chronic active hepatitis. Vox Sang 35:366–369, 1978

    PubMed  Google Scholar 

  102. Mackay IR, Tait BD: HLA associations with autoimmune-type chronic active hepatitis: Identification of B8-DRw3 haplotype by family studies. Gastroenterology 79:95–98, 1980

    PubMed  Google Scholar 

  103. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R: Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13:701–706, 1990

    Google Scholar 

  104. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507, 1993

    PubMed  Google Scholar 

  105. Mackay IR, Morris PJ: Association of autoimmune active chronic hepatitis with HL-A1,8. Lancet 2:793–795, 1972

    PubMed  Google Scholar 

  106. Ryder LP, Andersen E, Svejgaard A: An HLA map of Europe. Hum Hered 28:171–200, 1978

    PubMed  Google Scholar 

  107. Seki T, Kiyosawa K, Inoko H, Ota M: Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 12:1300–1304, 1990

    PubMed  Google Scholar 

  108. Czaja AJ, Rakela J, Hay JE, Moore SB: Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 98:1587–1593, 1990

    PubMed  Google Scholar 

  109. Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI: HLA determinants in chronic active liver disease: Possible relation of HLA-Dw3 to prognosis. Tissue Antigens 9:36–40, 1977

    PubMed  Google Scholar 

  110. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH: Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15:215–221, 1992

    PubMed  Google Scholar 

  111. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston ALWF, Mowat AP, Williams R: Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609–615, 1994

    PubMed  Google Scholar 

  112. Maddrey WC: How many types of autoimmune hepatitis are there? Gastroenterology 105:1571–1575, 1993 (editorial)

    PubMed  Google Scholar 

  113. Todd JA, Bell JI, McDevitt HO: HLA-DQB gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329:599–604, 1987

    PubMed  Google Scholar 

  114. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal, Thorsby E: Evidence for a primary association of celiac disease to a particular HLA-DQ A/B heterodimer. J Exp Med 169:345–350, 1989

    PubMed  Google Scholar 

  115. Tomer Y, Shoenfeld Y: The significance of natural autoantibodies. Immunol Invest 17:389–424, 1988

    PubMed  Google Scholar 

  116. Cochrane AMG, Moussouros A, Thomson AD, Eddleston ALWF, Williams R: Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet 1:441–444, 1976

    PubMed  Google Scholar 

  117. Vento S, Nouri-Aria KT, Eddleston ALWF: Immune mechanisms in autoimmune chronic active hepatitis. Scand J Gastroentol (suppl 114) 20:91–103, 1985

    Google Scholar 

  118. Eddleston ALWF: Immunology of chronic active hepatitis. QJM 55:191–198, 1985

    PubMed  Google Scholar 

  119. Nouri-Aria KJ, Hegarty JE, Alexander GJM, Eddleston ALWF, Williams R: Effect of corticosteroids on suppressor-cell activity in “autoimmune” and viral chronic active hepatitis. N Engl J Med 307:1301–1304, 1982

    PubMed  Google Scholar 

  120. Hodgson HJF, Wands JR, Isselbacher KJ: Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci USA 75:1549–1553, 1978

    PubMed  Google Scholar 

  121. Kakumu S, Yata K, Kashio T: Immunoregulatory T-cell function in acute and chronic liver disease. Gastroenterology 79:613–619, 1980

    PubMed  Google Scholar 

  122. Kashio T, Hotta R, Kakumu S: Lymphocyte suppressor cell activity in acute and chronic liver disease. Clin Exp Immunol 44:459–466, 1981

    PubMed  Google Scholar 

  123. Nonmura A, Tamimo M, Kurumaya H, Ohta G, Kato Y, Kobayashi K: Disordered immunoregulatory functions in patients with chronic active hepatitis. Clin Exp Immunol 47:595–605, 1982

    PubMed  Google Scholar 

  124. Czaja AJ, Wang KK, Shiels MT, Katzmann JA: Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol 17:180–186, 1993

    PubMed  Google Scholar 

  125. Galbraith RM, Smith M, Mackenzie RM, Tee DE, Doniach D, Williams R: High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med 290:63–69, 1974

    PubMed  Google Scholar 

  126. O'Brien CJ, Vento S, Donaldson PT, McSorley CG, McFarlane IG, Williams R, Eddleston ALWF: Cell-mediated immunity and suppressor-T-cell defects to liver-derived antigens in families of patients with autoimmune chronic active hepatitis. Lancet 1:350–353, 1986

    PubMed  Google Scholar 

  127. Nouri-Aria KT, Donaldson PT, Hegarty JE, Eddleston AWLF, Williams R: HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol 1:235–241, 1985

    PubMed  Google Scholar 

  128. Krawitt EL, Kilby AE, Albertini RJ, Schanfield MS, Chastenay BF, Harper PC, Mickey RM, McAuliffe TL: An immunogenetic study of suppressor cell activity in autoimmune chronic active hepatitis. Clin Immunol Immunopathol 46:249–257, 1988

    PubMed  Google Scholar 

  129. Vento S, Hegarty JE, Bottazzo G, Macchia E, Williams R, Eddleston ALWF: Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1:1200–1204, 1984

    PubMed  Google Scholar 

  130. Lobo-Yeo A, Mieli-Vergani G, Kenna G, Mowat AP, Vergani D: Evidence of impaired antigen non-specific but normal antigen specific suppressor cell function in children with autoimmune chronic active hepatitis. Clin Exp Immunol 70:411–416, 1987

    PubMed  Google Scholar 

  131. Colucci G, Colombo M, Del Ninno E, Paronetto F: In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. Gastroenterology 85:1138–1145, 1983

    PubMed  Google Scholar 

  132. Montano L, Aranguibel R, Boffill M, Goodall AH, Janossy G, Thomas HC: An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology 3:292–296, 1983

    PubMed  Google Scholar 

  133. Si L, Whiteside TL, Schade RR, Van Thiel DH: Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis (CAH). J Clin Immunol 3:408–419, 1983

    PubMed  Google Scholar 

  134. Frazer IH, Mackay IR, Bell J, Becker G: The cellular infiltrate in the liver in auto-immune chronic active hepatitis: Analysis with monoclonal antibodies. Liver 5:162–172, 1985

    PubMed  Google Scholar 

  135. Hashimoto E, Lindor KD, Homburger HA, Dickson ER, Czaja AJ, Wiesner RH, Ludwig J. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc 68:1049–1055, 1993

    PubMed  Google Scholar 

  136. Schwab R, Russo C, Weksler ME: Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 22:2989–2993, 1992

    PubMed  Google Scholar 

  137. Murasko DM, Goonewardene IM: T cell function in aging: Mechanisms of decline. Annu Rev Gerontol Geriatr 10:71–96, 1990

    PubMed  Google Scholar 

  138. Tomer Y, Shoenfeld Y: Ageing and autoantibodies. Autoimmunity 1:141–149, 1988

    PubMed  Google Scholar 

  139. Vento S, Garofano T, DiPerri G, Dolci L, Concia E, Bassetti D: Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible patients. Lancet 337:1183–1187, 1991

    PubMed  Google Scholar 

  140. Laskus T, Slusarczyk J: Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 34:1294–1297, 1989

    PubMed  Google Scholar 

  141. Ramadori G, Lohr H, Rossol S, Manns M, Meyer zum Buschenfelde K-H: Human immunodeficiency virus infection mimics autoimmune hepatitis—a case report. Klin Wochenschr 66:1040, 1988

    PubMed  Google Scholar 

  142. Berk L, Schalm SW, Heijtink RA: Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses. Gut 32:1198–1200, 1991

    PubMed  Google Scholar 

  143. Robertson DAF, Zhang SL, Guy EC, Wright R: Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 2:9–11, 1987

    PubMed  Google Scholar 

  144. Silva E, Sallie R, Tibbs C, McFarlane I, Johnson P, Williams R: Absence of hepatitis C virus in British patients with type 1 autoimmune chronic active hepatitis—a polymerase chain reaction and serological study. J Hepatol 19:211–215, 1993

    PubMed  Google Scholar 

  145. Mitchel LS, Jeffers LJ, Reddy KR, Cheinquer H, Coelho-Little E, Moreda R, Parker T, Silva M, Li XM, de Medina M, Coelho-Borges S, Hill M, Altman R, Manns MP, Schiff ER: Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II, and III. Am J Gastroentol 88:1027–1034, 1993

    Google Scholar 

  146. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER: Interfer-on-induced chronic active hepatitis? Gastroenterology 101:840–842, 1991

    PubMed  Google Scholar 

  147. Mackie FD, Peakman M, Yun M, Sallie R, Smith H, Davies ET, Mieli-Vergani G, Vergani D: Primary and secondary liver/kidney microsomal response following infection with hepatitis C virus. Gastroenterology 106:1672–1675, 1994

    PubMed  Google Scholar 

  148. Czaja AJ: Diagnosis, prognosis, and treatment of classical autoimmune chronic active hepatitis.In Autoimmune Liver Diseases. EL Krawitt, RH Wiesner (eds). New York, Raven Press, 1991, pp 143–166

    Google Scholar 

  149. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston ALWF, Williams R: Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3:685–689, 1983

    PubMed  Google Scholar 

  150. Stellon AJ, Keating JJ, Johnson PJ, MacFarlane IG, Williams R: Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 8:781–784, 1988

    PubMed  Google Scholar 

  151. Czaja AJ: Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11:1044–1049, 1990

    PubMed  Google Scholar 

  152. Canafax DM, Ascher NL: Cyclosporine immunosuppression. Clin Pharmacol 2:515–524, 1983

    Google Scholar 

  153. Faulds D, Goa KL, Benfield P: Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45:953–1040, 1993

    PubMed  Google Scholar 

  154. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW: Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 143:463–465, 1985

    PubMed  Google Scholar 

  155. Hyams JS, Ballow M, Leichtner AM: Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 93:890–893, 1987

    PubMed  Google Scholar 

  156. Thomson AW: FK-506: profile of an important new immunosuppressant. Transplantation Reviews 4:1–13, 1990

    Google Scholar 

  157. Peters DH, Fitton A, Plosker GL, Faulds D: Tacrolimus: A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46:746–794, 1993

    PubMed  Google Scholar 

  158. Thomson AW, Carroll PB, McCauley J, Woo J, Abu-Elmagd K, Starzl TE, Van Thiel DH: FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol 14:323–344, 1993

    PubMed  Google Scholar 

  159. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, Starzl TE: FK 506 in the treatment of autoimmune chronic active hepatitis: Preliminary results. Am J Gastroenterology 87:1309, 1992 (abstract)

    Google Scholar 

  160. Hegarty JE, Nouri-Aria KT, Eddleston ALWF, Williams R: Controlled trial of a thymic hormone extract (Thymostimulin) in “autoimmune” chronic active hepatitis. Gut 25:279–283, 1984

    PubMed  Google Scholar 

  161. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, Waggoner JG, Hoofnagle JH, Shafritz DA: Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology 14:409–415, 1991

    PubMed  Google Scholar 

  162. Jenkins PJ, Portmann BP, Eddleston ALWF, Williams R: Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: Results of prospective double-blind controlled trial. Liver 2:77–81, 1982

    PubMed  Google Scholar 

  163. Neuberger J, Hegarty JE, Eddleston ALWF, Williams R: Effect of polyunsaturated phosphatidylcholine on immune mediated hepatocyte damage. Gut 24:751–755, 1983

    PubMed  Google Scholar 

  164. Miracco A, Iodice G, Peluso C, Quarentelli A, Selce P, Tedesco A, Pastore P: Arginine thiazolidinecarboxylate in the treatment of chronic active hepatitis: Double-blind comparison with placebo. J Int Med Res 12:35–39, 1984

    PubMed  Google Scholar 

  165. Crosignani A, Battezzati PM, Setchell KDR, Camisasca M, Bertolini E, Roda A, Zuin M, Podda M: Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology 13:339–344, 1991

    PubMed  Google Scholar 

  166. Heumann DM, Pandak WM, Hylemon PB, Vlahcevic ZR: Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts:In vivo studies in rat hepatocytes and human erythrocytes. Hepatology 14:920–926, 1991

    PubMed  Google Scholar 

  167. Marteau P, Chazouilleres O, Myara A, Jian R, Rambaud J-C, Poupon R: Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 12:1206–1208, 1990

    PubMed  Google Scholar 

  168. Calmus Y, Gane P, Rouger P, Poupon R: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11:12–15, 1990

    PubMed  Google Scholar 

  169. Schwartsmann G, Peters GJ, Laurensse E, de Waal FC, Loonen AH, Leyva A, Pinedo HM: DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochem Pharmacol 37:3257–3266, 1988

    PubMed  Google Scholar 

  170. Cramer DV, Chapman FA, Jaffee BD, Jones EA, Knoop M, Hreha-Eiras G, Makowka L: The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 53:303–308, 1992

    PubMed  Google Scholar 

  171. Bierer BE, Jin YJ, Fruman DA, Calvo V, Burakoff SJ: FK 506 and rapamycin: molecular probes of T-lymphocyte activation. Transplant Proc 23:2850–2855, 1991

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czaja, A.J. Autoimmune hepatitis. Digest Dis Sci 40, 435–456 (1995). https://doi.org/10.1007/BF02065434

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02065434

Key words

Navigation